Affymax, (FRA:A5Y) Stock Based Compensation : €1.30 Mil (TTM As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Affymax, Stock Based Compensation?

Affymax,'s Stock Based Compensation for the three months ended in Jun. 2014 was €0.22 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2014 was €1.30 Mil.

Affymax, Stock Based Compensation Historical Data

The historical data trend for Affymax,'s Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Stock Based Compensation Chart

Affymax, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Stock Based Compensation

Get a 7-Day Free Trial

7.66

8.71

7.62

8.54

3.24

Affymax, Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Stock Based Compensation	Get a 7-Day Free Trial															-0.21	0.10	0.64	0.35	0.22

Affymax, Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.30 Mil.

Affymax, Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Affymax,'s Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax, (FRA:A5Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines